Figure 1. AT and NLRP3 Inhibition Promotes Bacterial Clearance.

(A) S. aureus CFUs recovered from the lungs of infected (1e8 CFUs) mice treated with MEDI4893* (15 mg/kg) or c-IgG 24 hr prior to infection.

(B) IL-1β levels in BALF 4 and 24 hr following infection (1e8 CFUs) in mice treated with MEDI4893* (15 mg/kg) or c-IgG 24 hr prior to infection.

(C) S. aureus CFUs recovered from the lungs of infected (5e7 CFUs) mice treated with MEDI4893* (15 mg/kg) or c-IgG 24 hr prior to infection.

(D) IL-1β levels in BALF 4 and 24 hr following infection (5e7 CFUs) in mice treated with MEDI4893* (15 mg/kg) or c-IgG 24 hr prior to infection.

(E) Survival of mice treated with Anakinra or c-IgG and infected with 1e8 CFUs S. aureus.

(F) S. aureus CFUs recovered from the lungs of infected (5e7 CFUs) mice treated with Anakinra or c-IgG 24 hr prior to infection.

(G) Survival of mice treated with anti-IL-18 mAb or c-IgG and infected with 1e8 CFUs S. aureus.

(H) S. aureus CFUs recovered from the lungs of infected (5e7 CFUs) mice treated with anti-IL-18 mAb or c-IgG 24 hr prior to infection.

(I) Survival of mice treated with both Anakinra and anti-IL-18 mAb, or c-IgG and infected with 1e8 CFUs S. aureus.

(J) S. aureus CFUs recovered from the lungs of infected (5e7 CFUs) mice treated with both Anakinra and anti-IL-18 mAb, or c-IgG 24 hr prior to infection.

(K) Survival of mice treated (1 hr prior to infection) with MCC950 or vehicle control (DMSO) and infected with 1e8 CFUs S. aureus.

(L) S. aureus CFUs recovered from the lungs of infected (5e7 CFUs) mice treated (1 hr prior to infection) with MCC950 or vehicle control (DMSO).

Statistical significance was determined by (A–D, F, H, J, and L) Mann-Whitney test or (E, G, I, and K) log-rank test. All data are representative of greater than 2 independent experiments and n ≥ 10 mice per group per experiment.